Trial Profile

A clinical trial of Equecabtagene-autoleucel for treatment to generalized myasthenia gravis (gMG)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 11 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Equecabtagene autoleucel (Primary)
Indications Myasthenia gravis
Focus Adverse reactions

Most Recent Events

11 Apr 2024 New trial record
04 Apr 2024 According to an IASO BioMed media release, the Investigational New Drug (IND) application for its BCMA CAR-T (Equecabtagene Autoleucel, Eque-cel) has been approved by the U.S. Food and Drug Administration (FDA) for use in U.S. clinical trials for generalized myasthenia gravis (gMG).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com